Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
2.470
-0.060 (-2.37%)
At close: Jun 24, 2026, 4:00 PM EDT
2.440
-0.030 (-1.21%)
After-hours: Jun 24, 2026, 5:48 PM EDT
Lipocine Employees
Lipocine had 14 employees as of December 31, 2025. The number of employees decreased by 2 or -12.50% compared to the previous year.
Employees
14
Change (1Y)
-2
Growth (1Y)
-12.50%
Revenue / Employee
$143,015
Profits / Employee
-$816,752
Market Cap
20.36M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | -2 | -12.50% |
| Dec 31, 2024 | 16 | -1 | -5.88% |
| Dec 31, 2023 | 17 | 0 | - |
| Dec 31, 2022 | 17 | 4 | 30.77% |
| Sep 30, 2022 | 17 | 4 | 30.77% |
| Jun 30, 2022 | 15 | 2 | 15.38% |
| Mar 31, 2022 | 13 | 0 | - |
| Dec 31, 2021 | 13 | 2 | 18.18% |
| Sep 30, 2021 | 13 | 2 | 18.18% |
| Jun 30, 2021 | 13 | - | - |
| Mar 31, 2021 | 13 | 1 | 8.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Werewolf Therapeutics | 39 |
| Lunai Bioworks | 29 |
| Palatin Technologies | 29 |
| Passage Bio | 24 |
| NewcelX | 12 |
| Cellectar Biosciences | 11 |
| Tempest Therapeutics | 5 |
| Pasithea Therapeutics | 5 |
LPCN News
- 12 days ago - Lipocine Transcript: KOL event - Transcripts
- 12 days ago - Lipocine Slides: KOL event - Filings
- 20 days ago - Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 - PRNewsWire
- 5 weeks ago - Lipocine Transcript: A.G.P.'s Annual Virtual Healthcare Conference - Transcripts
- 5 weeks ago - Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting - PRNewsWire
- 5 weeks ago - Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer - GlobeNewsWire
- 5 weeks ago - Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase - PRNewsWire
- 6 weeks ago - Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 - PRNewsWire